Antibiotic may control rare eye cancer without chemo

NCT ID NCT01820910

Completed Disease control Sponsor: International Extranodal Lymphoma Study Group (IELSG) Source: ClinicalTrials.gov ↗

First seen Jan 27, 2026 · Last updated May 14, 2026 · Updated 17 times

Summary

This study tested whether the antibiotic doxycycline can control a rare lymphoma of the eye that is linked to a bacterial infection. 44 newly diagnosed patients received prolonged doxycycline, and if the infection returned, they were retreated. The goal was to see how long the cancer stayed under control. The approach aims to manage the disease without chemotherapy, but ongoing monitoring and possible retreatment are needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA OF OCULAR ADNEXAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AO Ospedali Riuniti Papardo Piemonte

Messina, Italy
Ematologia

Parma, Italy
Molinette 1

Torino, Italy
Ospedale Civile

Piacenza, Italy
Ospedale San Raffaele

Milan, Italy
Ospedale dell'Angelo

Venezia, Italy
Spedali Civili Di Brescia

Brescia, Italy
Università La Sapienza

Rome, Italy

Conditions

Explore the condition pages connected to this study.

MARGINAL ZONE LYMPHOMA OF OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA OF OCULAR ADNEXAL